Neutral
Wolfe Research analyst Alexandria Hammond raised the price target for Pfizer Inc. (PFE) from $25 to $26, while maintaining an Underperform rating, des...
Pfizer (PFE) stock is currently trading at US$25.33, indicating an estimated intrinsic discount of 58% and a narrative fair value of $30.62. This sugg...
Bullish
The European Commission has approved Pfizer's HYMPAVZI (marstacimab) to expand its indication for adults and adolescents aged 12 and older with hemoph...
Bullish
Pfizer Ltd, the Indian subsidiary of Pfizer Inc., is a key player in India's fast-growing pharmaceutical market, focusing on oncology and vaccines. Th...
Bullish
Arvinas Inc. and Pfizer Inc. have entered into a license agreement with Rigel Pharmaceuticals Inc. to transfer exclusive global development, manufactu...
Bullish
Arvinas and Pfizer have licensed the global rights for their FDA-approved breast cancer drug, VEPPANU, to Rigel Pharmaceuticals in a deal worth up to ...
Bullish
Despite healthy numbers, Pfizer's recent earnings announcement underwhelmed the market. Analysis suggests that a significant expense from "unusual ite...
Neutral
Pfizer reported strong first-quarter 2026 results, with revenue up and reaffirmed full-year guidance, while also advancing its oncology pipeline and s...
Neutral
Chesapeake Capital Corp IL acquired a new stake in Pfizer Inc. (NYSE:PFE – Free Report) in the 4th quarter, according to the company in its most recen...
Neutral
Cheviot Value Management LLC grew its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 12.0% in the 4th quarter, according to the company...
Bullish
Pfizer exceeded Wall Street's first-quarter profit estimates, driven by robust demand for established medications like the blood thinner Eliquis and t...
Bullish
Pfizer has extended the market exclusivity for its cardiomyopathy drug, VYNDAMAX, until June 1, 2031, following a patent dispute settlement. This deve...
Pfizer (PFE) is under valuation scrutiny after new oncology data and FDA Priority Review for its bladder cancer regimen. Despite recent positive momen...
Pfizer director Susan Desmond-Hellmann was granted 7,686.539 phantom stock units as part of her deferred board compensation. Each unit is linked to on...
Neutral
Pfizer Inc. (PFE) has filed a Form 8-K with the SEC on April 23, 2026, to provide essential updates and disclosures to investors and stakeholders. The...
Pfizer Inc. director Mortimer J. Buckley was granted 7,686.539 phantom stock units as deferred compensation, increasing his total phantom units to 24,...
Neutral
Pfizer Inc. (PFE) is highlighted as one of the best Fortune 500 dividend stocks, boasting an annual dividend yield of 6.37%. The company recently decl...
Neutral
Pfizer Inc. director James C. Smith was granted 7,686.539 Phantom Stock Units as deferred compensation, valued at $26.67 per unit. These units, which ...
Neutral
Calamos Advisors LLC increased its holdings in Pfizer Inc. by 3.2% in the fourth quarter, bringing its total stake to 1,919,276 shares valued at $47.7...
Neutral
Pfizer is set to unveil significant oncology pipeline updates at the ASCO 2026 Annual Meeting, showcasing new clinical data for several marketed and p...